Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study

Once-Weekly Semaglutide in Adults with Overweight or Obesity

John Wilding, Rachel L. Batterham, Salvatore Calanna et al. · New England Journal of Medicine · 2021 · 4.5K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

Melanie J. Davies, Louise Færch, Ole Kleist Jeppesen et al. · The Lancet · 2021 · 1.3K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

Kishore M. Gadde, David B. Allison, Donna H. Ryan et al. · The Lancet · 2011 · 1K citations

Medicine, Pharmacology, Pharmacotherapy +10

Weight regain and cardiometabolic effects after withdrawal of semaglutide: The <scp>STEP</scp> 1 trial extension

John Wilding, Rachel L. Batterham, Melanie J. Davies et al. · Diabetes Obesity and Metabolism · 2022 · 921 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes

JAMA · 2022 · 881 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17